- Home
- GALT
as 12-17-2024 4:00pm EST
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | 147.8M | IPO Year: | N/A |
| Target Price: | $11.00 | AVG Volume (30 days): | 549.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.56 - $4.27 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ELDRED KARY | GALT | Director | Oct 23 '24 | Buy | $2.60 | 500 | $1,300.00 | 50,213 | |
| FREEMAN KEVIN D | GALT | Director | Oct 17 '24 | Buy | $2.64 | 1,300 | $3,432.00 | 34,769 | |
| FREEMAN KEVIN D | GALT | Director | Oct 16 '24 | Buy | $2.70 | 10,000 | $27,000.00 | 34,769 |
Latest Galectin Therapeutics Inc. News
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks
GlobeNewswire
a month ago
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
GlobeNewswire
a month ago
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 10/17/2024
GlobeNewswire
2 months ago
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
GlobeNewswire
3 months ago
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
GlobeNewswire
3 months ago
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
4 months ago
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Compare GALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.